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E-mail address: e.struys@vumc.nl (E.A. Struys).The mammalian degradation of lysine is believed to proceed via two distinct routes, the saccharo-
pine and the pipecolic acid routes, that ultimately converge at the level of a-aminoadipic semialde-
hyde (a-AASA). a-AASA dehydrogenase-deﬁcient ﬁbroblasts were grown in cell culture medium
supplemented with either L-[a-15N]lysine or L-[e-15N]lysine to explore the exact route of lysine deg-
radation. L-[a-15N]lysine was catabolised into [15N]saccharopine, [15N]a-AASA, [15N]D1-piperideine-
6-carboxylate, and surprisingly in [15N]pipecolic acid, whereas L-[e-15N]lysine resulted only in the
formation of [15N]saccharopine. These results imply that lysine is exclusively degraded in ﬁbroblasts
via the saccharopine branch, and pipecolic acid originates from an alternative precursor. We
hypothesize that pipecolic acid derives from D1-piperideine-6-carboxylate by the action of D1-pyr-
roline-5-carboxylic acid reductase, an enzyme involved in proline metabolism.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In mammals, L-lysine (an essential a,e-dibasic amino acid) is
catabolised by distinct yet convergent branches. In what is be-
lieved to be the main catabolic route [1–3], L-lysine is converted
into saccharopine by the action of the bifunctional enzyme a-ami-
noadipic semialdehyde synthase (AASS) (Fig. 1). For this reaction
2-ketoglutaric acid is a mandatory co-substrate. Saccharopine is
further metabolized by AASS into a-aminoadipic semialdehyde
(a-AASA) in a reaction in which glutamic acid is produced. The
net result of this two-step metabolic process is the e-deamination
of L-lysine. Alternatively, L-lysine is metabolized via an a-deamina-
tion yielding 2-keto-6-aminocaproic acid, which is in equilibrium
with its cyclic form D1-piperideine-2-carboxylate. The latter is
converted into L-pipecolic acid which is metabolized by pipecolic
acid oxidase to D1-piperideine-6-carboxylate, which is in equilib-
rium with a-AASA. At this stage the two catabolic routes converge,
and a-AASA is converted to a-aminoadipic acid (a-AAA) by a-ami-
noadipic semialdehyde dehydrogenase, also named Antiquitin.
Current knowledge of mammalian L-lysine catabolism is based
upon multiple studies in different species in which [14C] labeled ly-
sine was used as tracer [4,5]. The use of [14C] labeled L-lysine inchemical Societies. Published by Ethese experiments facilitated the use of liquid chromatography
coupled to scintillation spectrophotometry, facilitating the detec-
tion of downstream of [14C] labeled metabolites. However, a major
drawback of the use of [14C] labeled L-lysine is the lack of speciﬁc
information characterizing speciﬁc degradation pathways, thus
hampering result interpretation. Recently, the genetic defect for
the majority of patients with pyridoxine dependent epilepsy
(PDE) was attributed to mutations in the Antiquitin gene which re-
sults in a-AASA dehydrogenase deﬁciency, making PDE a disorder
in L-lysine catabolism [6]. a-AASA dehydrogenase deﬁciency re-
sults in the accumulation of pathognomonic a-AASA (in cerebro-
spinal ﬂuid (CSF), plasma and urine) and pipecolic acid (CSF and
plasma) in affected patients [7–9]. Pilot experiments using ﬁbro-
blasts derived from patients with a-AASA dehydrogenase deﬁ-
ciency veriﬁed that the defect is also expressed in these cells,
based upon the accumulation of a-AASA and decreased formation
of a-AAA. Accordingly, cultured ﬁbroblasts represent a model sys-
tem in which there is a metabolic block at the level where the two
branches of lysine catabolism converge, making this cell type a
useful system in which to study L-lysine metabolism using sensi-
tive GC–MS and LC–MS/MS and stable-isotope methods available
in our laboratory.
In the current study, we sought to discriminate the labeling pat-
tern of the two branches of L-lysine catabolism using a-AASA dehy-






























Fig. 1. Currently accepted metabolic pathway for the conversion of L-lysine in mammals, depicted to the level of AAA.
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L-[e-15N]lysine. Theoretically, incubation experiments performed
with L-[a-15N]lysine yield [15N] incorporation in saccharopine,
a-AASA, P6C and a-AAA should lysine metabolize via the saccharo-
pine pathway. Conversely, incubation experiments with
L-[e-15N]lysine should yield [15N] incorporation into saccharopine,
but not a-AASA and a-AAA, if the precursor is metabolized via the
saccharopine pathway.
Metabolism of L-[e-15N]lysine via the pipecolic acid pathway
route should yield [15N] incorporation into pipecolic acid, P6C,
a-AASA and a-AAA but not in saccharopine. Based upon these
hypotheses, the current metabolic investigations were
undertaken.2. Materials and methods
2.1. Chemicals
Stable isotope labeled L-[a-15N]lysine (95–99% purity),
L-[e-15N]lysine (98% purity), and L-[U-13C]lysine (98% purity) were
purchased from Cambridge Isotope Laboratories, (Andover, MA,
USA). The exact location of the [15N] labeling in L-[a-15N]lysine
and L-[e-15N]lysine was veriﬁed using L-[a-15N]lysine and
L-[e-15N]lysine stock solutions. L-[a-15N]lysine and L-[e-15N]lysine
were converted into their di-N-triﬂuoroacetyl-methyl derivatives
and analyzed by GC–MS operating in the electron impact mode.
The GC–MS spectra obtained were compared to GC–MS spectra
Table 1
MPE’s (%) in the different lysine metabolites following incubation with L-[a-15N]lysine. The expressed values are the average of two independent incubation experiments (Nd
indicates no detectable enrichments, i.e. <5%).
Cell line Pipecolic acid Saccharopine a-AASA P6C a-AAA
a-AASA dehydrogenase deﬁcient I 47 40 41 51 nd
a-AASA dehydrogenase deﬁcient II 45 41 45 48 nd
GA I nd 39 44 48 41
Table 2
MPE’s (%) in different lysine metabolites following incubation with L-[e-15N]lysine. The expressed values are the average of two independent incubation experiments (Nd
indicates no detectable enrichments, i.e. <5%).
Cell line Pipecolic acid Saccharopine a-AASA P6C a-AAA
a-AASA dehydrogenase deﬁcient I nd 33 nd nd nd
a-AASA dehydrogenase deﬁcient II nd 24 nd nd nd
GA I nd 28 nd nd nd
Fig. 2. Formation of [U-13C6]a-AASA as a function of increasing [U-13C6]lysine
concentration.
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cal, indicating that the two forms of [15N]labeled lysine were in-
deed uniquely labeled in the proper nitrogen.
Lysine-free cell culture mediumwas prepared on request by ITK
Diagnostics (Uithoorn, The Netherlands). All other chemicals and
reagents used were of the highest quality available.
2.2. Fibroblast cell line and culturing procedure
Three ﬁbroblast cell lines were employed in this study, i.e. two
with a-AASA dehydrogenase deﬁciency and one with glutaric aci-
duria type I (another defect in lysine catabolism downstream of
AASA dehydrogenase deﬁciency). Fibroblasts were cultured
according to standardized protocols. For incubation experiments,
ﬁbroblasts were harvested by trypsination and few cells were
transferred to a 75 cm2 ﬂask. The use of a small cell number signif-
icantly limited the inﬂuence of intracellular accumulation of non-
labeled metabolites during the logarithmic growth phase of the
cells, which would result in dilution of the isotopic enrichments.
Subsequently, sterilized L-[a-15N]lysine or L-[e-15N]lysine (experi-
ments performed in duplicate for each ﬁbroblast cell line) was
added to cell cultures at a 1:1 ratio equal to the L-lysine concentra-
tion already present (i.e. 167 lM). As control, each cell line wasMPE ¼ corrected peak area of
15N-isotopomer
corrected peak area of 15N-isotopomerþ peak area non-labelecultured without labeled substrates. Fibroblasts were grown to
conﬂuency, after which the cell culture medium was collected
and stored at 20 C. Cells were harvested by trypsination, washed
with HBSS and stored at 20 C.
2.3. Mass isotopomer analysis of pipecolic acid, P6C, saccharopine, a-
AASA, and a-AAA
Pipecolic acid was determined by GC–MS according to a modiﬁ-
cation of the procedure of Kok et al. employing negative chemical
ionization mass fragmentography [10]. To 500 lL of cell culture
medium, 0.01 nmol [2H9]pipecolic acid was added as internal stan-
dard. Pipecolic acid, [15N]pipecolicacid, and [2H9]pipecolic acidwere
monitored by recording the traces of m/z 186, m/z 187 and m/z
195, respectively. For P6C measurement, culture medium was di-
luted 10with demineralised water and 5 lL was injected onto an
Xterra HPLC column (3.9  150 mm, 5 lM particles) using 5%
MeOH/H2O (containing0.025% formicacid) asmobilephaseat aﬂow
rate of 0.8 ml/min. P6C was detected using an API 3000MS/MS (Ap-
plied Biosystems) equippedwith TurboIon electrospray operating in
the positive mode. The MRM transitions m/z 128.1 > 82 and
129.1 > 83 were used for the detection of P6C and [15N]P6C, respec-
tively. Saccharopine,a-AASA, anda-AAAweremeasured by LC–MS/
MS as previously described employing an FMOC derivatisation pro-
cedure [6]. For the measurements of a-AASA and a-AAA, culture
medium was deproteinized using an Amicon centrifuge ﬁlter
and100 lL of borate buffer (pH 10) plus 100 lL of FMOC reagent
(1.5 mg/ml FMOC in acetone) were added to 50 lL of the ﬁltrate.
Subsequently, 5 lL was injected onto the LC–MS/MS system.
[15N]Saccharopine could not be assessed inﬁbroblast culturemedia;
however, we were able to measure intracellular [15N]saccharopine
by the same derivatisation procedure as described for a-AASA and
a-AAAusing 50 lL of cell extract. TheMRM transitions for saccharo-
pine and [15N]saccharopine were: m/z 497.2 > 257.2 and m/z
498.2 > 258.2; for a-AASA and [15N]a-AASA: m/z 366.1 >
170.1 and m/z 367.1 > 171.1, and for a-AAA and [15N]a-AAA
m/z382.1 > 186.1 andm/z383.1 > 187.1. In all analyte deter-
minations, L-[a-15N]lysine and L-[e-15N]lysine stock solutions were
included to investigate the possible presence of trace amounts of
15N-labeled lysine degradation intermediates. 15N-Enrichment was
expressed as Molar Percentage Excess (MPE) by the equation:d analyte
 100% ð1Þ
184 E.A. Struys, C. Jakobs / FEBS Letters 584 (2010) 181–186in which the corrected peak area of 15N-isotopomer indicates the
correction of the peak area for the contribution of the natural
occurring ﬁrst isotope of the speciﬁc analyte.
3. Results
Incubation of ﬁbroblast cell lines with L-[a-15N]lysine resulted
in the formation of [15N]saccharopine, [15N]a-AASA, and [15N]P6C
(Table 1). [15N]Pipecolic acid was detectable in the ﬁbroblast media
of a-AASA dehydrogenase-deﬁcient cell lines only, whereas the
formation of [15N]a-AAA was only detectable for the glutaric aci-
duria type I cell line. The observed enrichments for lysine metabo-







alpha aminoadipic semialdehyde dehydrogenas
Fig. 3. Metabolism of L-[a-15N]lysine in a-AASA dehydrogenase-deﬁcient ﬁbroblasts, sho
incorporation of [15N] in pipecolic acid is most likely the result of the reduction of [15Nvalue of 50%. It is noteworthy that both AAA and pipecolic acid
were present in considerable amounts in normal culture medium,
and the formation of non-labeled AAA and pipecolic acid in incuba-
tion experiments with [15N]labeled lysine were corrected accord-
ingly. Incubation of cell lines with L-[e-15N]lysine resulted in
formation of only [15N]saccharopine, with no incorporation of
[15N] in a-AASA, P6C, a-AAA, and pipecolic acid (Table 2). The
MPE values for [15N]saccharopine were lower than would be
expected.
In experiments carried out with L-[e-15N]lysine, we observed an
1.5–2-fold increase in the formation of non-labeled a-AASA with
L-[e-15N]lysine incubation versus blank experiments. Additionally,























wing that L-[a-15N]lysine is only degraded through the saccharopine pathway. The
]P6C by P5C reductase.
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labeled) compared to controls. Based upon these ﬁndings, we fur-
ther investigated the relationship between L-lysine content of the
ﬁbroblast culture medium and the formation of a-AASA. We uti-
lized custom made L-lysine-free ﬁbroblast culture medium and
supplemented this with increasing amounts of L-[U-13C6]lysine.
L-[U-13C6]lysine was used in lieu of L-[15N]lysine to allow better
quantiﬁcation of [U-13C6]-a-AASA production (no correction for
the ﬁrst natural isotope is required with L-[U-13C6]lysine). This
experiment was performed using an a-AASA dehydrogenase-deﬁ-
cient ﬁbroblast cell line, which was cultured as described in Sec-
tion 2. [U-13C6]a-AASA in the culture medium was quantiﬁed
relative to internal standard ([15N]-a-AAA Chemotrade, Germany).
The formation of [U-13C6]a-AASA was directly dependent upon
the concentration of [U-13C6]lysine added to the culture medium
(Fig 2). There was no signiﬁcant difference in ﬁbroblast growth
over the range of 0.05–4 mM L-[U-13C6]lysine. However, ﬁbroblasts
grown in non-L-[U-13C6]lysine supplemented medium displayed
retarded growth.4. Discussion
Fibroblasts derived from individuals deﬁcient in a-AASA dehy-
drogenase metabolize L-[a-15N]lysine into saccharopine, a-AASA,
P6C. Surprisingly, [15N]pipecolic acid was also formed from
L-[a-15N]lysine with MPE’s comparable to those of other metabo-
lites. In contrast, when using L-[e-15N]lysine, only saccharopine
was detected. Our alternate labeling strategy indicates that lysine
is metabolized exclusively through the saccharopine pathway in
ﬁbroblasts, although enrichments of <5% would not be quantiﬁed.
If lysine would have been at least partially metabolized via the pip-
ecolic acid pathway, [15N] incorporation would have been expected
in pipecolic acid, a-AASA, P6C and a-AAA, which was not the case.
Additionally, degradation of L-[a-15N]lysine via the pipecolic acid
pathway would not result in the formation of saccharopine,
a-AASA, P6C and a-AAA, since a-deamination in the ﬁrst step of ly-
sine degradation via this reaction sequence removes the [15N]label.
The formation of [15N]pipecolic acid from L-[a-15N]lysine is a
surprising result and suggests an alternative metabolic route for
the formation of pipecolic acid in ﬁbroblasts (Fig. 3). We speculate
that [15N]pipecolic acid is formed from accumulated P6C by the ac-
tion of pyrroline-5-carboxylate (P5C) reductase. Normally, this en-
zyme catalyzes the conversion of D1-pyrroline-5-carboxylate to
proline using NAD(P)H as cofactor. Thus far, the conversion of
P6C into pipecolic acid via P5C reductase activity has not been re-
ported in humans. In Escherichia coli overexpression experiments,
Fujii et al. showed that P6C, derived from lysine by the action of ly-
sine amino transferase (LAT), is converted to pipecolic acid in the
presence of P5C reductase [11]. There is no available evidence for
the existence of human P6C reductase. Ghadimi et al. studied
[14C]lysine metabolism in extracts of human and dog liver and
found [14C]saccharopine as the main metabolic product, with trace
amounts of [14C]pipecolic acid [4]. These authors concluded that
lysine is preferentially metabolized via the saccharopine pathway
in human liver, with metabolism via the pipecolic acid pathway
as a minor metabolic route. Our hypothesis for pipecolic acid pro-
duction via P5C reductase might also explain the formation of
[14C]pipecolic acid in the study of Ghadimi et al. [4]. Studies with
[U-13C6]lysine revealed a direct correlation between substrate con-
centration and the formation of [U-13C6]a-AASA. Children affected
with PDE require life-long pyridoxine supplementation to prevent
seizures. Despite this, the long term cognitive prognosis remains
poor. This may be a consequence of chronic metabolite intoxica-
tion upstream of the metabolic block, and our ﬁbroblast results
suggest that dietary lysine restriction may lower the ﬂux throughthe lysine pathway, yielding a net decrease in presumably toxic
intermediates.
Although our data argue against the existence of the pipecolic
acid pathway of lysine metabolism in ﬁbroblasts, we cannot extend
our ﬁndings to other tissues. The literature suggests that the pipe-
colic acid pathway is expressed in mammalian brain, while the
brain saccharopine pathway is active neonatally but declines with
age [12]. Increased plasma pipecolic acid in patients with familial
hyperlysinemia (AASS deﬁciency) supports the existence of the
pipecolic acid pathway in humans [13]. However, massive
elevation of lysine in these patients might give rise to nonspeciﬁc
a-deamination of lysine, comparable to the process observed in
hepatic methionine adenosyltransferase deﬁciency where supra
physiological levels of methionine are a-deaminated to 2-keto-4-
methylthiobutyrate [14]. The importance of the brain saccharopine
pathway can also be inferred from biochemical observations in pa-
tients with L-2-hydroxyglutaric aciduria, a disorder linked to defec-
tive conversion of L-2-hydroxyglutaric acid to 2-ketoglutaric acid.
These patients manifest consistent increases of CSF lysine associ-
ated with a decreased availability of 2-ketoglutaric acid, which is
needed for the conversion of lysine to saccharopine [15].
Patients with a-AASA dehydrogenase deﬁciency also accumu-
late pipecolic acid in CSF, which has been attributed to the meta-
bolic block downstream of the pipecolic acid pathway. Our
results, however, suggest that increased pipecolic acid may reﬂect
accumulation of P6C, which is converted to pipecolic acid by P5C
reductase. This possible reaction sequence raises questions about
the metabolic role of pipecolic acid oxidase. Since no metabolic
function for pipecolic acid is known, pipecolic acid oxidase may
act as an enzyme of metabolite repair [16], reconverting pipecolic
acid into P6C. Future experiments in our laboratory will focus on
lysine metabolism in other cell types, including hepatocytes and
astrocytes, as well as leucocytes, and on further elucidation of
the kinetic parameters for the conversion of P6C to pipecolic acid
by P5C reductase.Acknowledgements
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